News
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. | Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech
The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.
The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...
This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...
Stocktwits on MSN3d
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca
Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...
US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...
2don MSN
What to know about mRNA vaccines
WASHINGTON -- So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using ...
Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...
1d
UPenn, where mRNA vaccine tech was pioneered, will not lose funding as feds cut $500M in mRNA grants
There have been no changes to the licensing and royalty agreements related to mRNA research that have netted the university ...
Health Secretary Robert F. Kennedy Jr.’s decision this week to cancel hundreds of millions of dollars in mRNA vaccine funding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback